Ionetix Corporation, a Lansing, Mich.-based cyclotron know-how innovator and isotope producer for diagnostic and therapeutic purposes, obtained a financing of undisclosed amoint.
Backers had been Eli Lilly and Firm, in addition to present shareholders led by Tees River Restricted.
The corporate intends to make use of the funds for continued improvement of its core know-how choices and enlargement of the present cyclotron community in assist of its strategic development plans within the late-stage scientific and industrial settings.
Led by Kevin Cameron, Chief Govt Officer, Ionetix makes use of its proprietary cyclotron know-how platform to develop progressive options that allow entry to scarce radioisotopes used for each diagnostic and therapeutic radiopharmaceuticals. Ionetix presents each high-purity Actinium-225 (Ac-225) and Astatine-211 (At-211) to be used in focused alpha therapies. The corporate additionally supplies N-13, F-18 and Ga-68 for diagnostic imaging. Its distribution provide chain contains contract drug manufacturing and “white glove” distribution logistics, permitting international entry to those imaging brokers and focused radiotherapies.
The financing follows prior Actinium provide and convertible debt agreements with Level Biopharma, which has since been acquired by Lilly.
FinSMEs
07/08/2024
